Anticancer (cytotoxic, anticlonogenic, antimetastatic, immunomodulatory actions) properties of 3,5‐dibromosalicylaldehyde against glioblastoma cells and DFT analyses (FT‐IR, Raman, NMR, UV) as well as a molecular docking study
Biology of the Cell · 2025
DOI: 10.1111/boc.202400138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of the Cell, 2025. Verfasst von Ebru Karakaş Sarıkaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Sciences, Necmettin Erbakan University, Konya, Türkiye. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents, Aldehydes. Die Arbeit nennt 101 Literaturangaben.
Abstract (Originalsprache)
Background
Information The primary objectives of this study were to characterize 3,5‐dibromosalicylaldehyde (3,5‐DBSA) and, investigate its antiproliferative, antimetastatic, cytotoxic, and immunoregulatory properties. NMR, Raman, UV, and FT‐IR spectroscopies were used to characterize 3,5‐DBSA. Potential conformations of 3,5‐DBSA were evaluated using Spartan's MMFF method. Geometry optimization calculations using Gaussian software calculated conformation energy values.
Results
Subsequently, Raman, FT‐IR, UV (ethanol) and NMR (DMSO) parameters were calculated. The experimental spectrum was compared to theoretical spectroscopic data. The present investigation investigated 3,5‐DBSA's anticancer properties; therefore, docking was done once the stable structure had been identified.
Conclusion
Identifying stable structure is crucial to molecular docking studies. In order to identify the mechanism by which 3,5‐DBSA binds to PI3K as a therapeutic target, molecular docking was utilized. This work is the first to show that 3,5‐DBSA is cytotoxic, anticlonogenic, antimetastatic, and immunomodulatory in glioblastoma cell line U87MG compared to healthy fibroblast L929 cells. Cytotoxicity and anti‐clonogenicity studies investigated 3,5‐DBSA's antiproliferative activities, whereas wound healing assays assessed cell migration. The immunomodulatory effects of 3,5‐DBSA in glioblastoma were assessed by measuring Netrin‐1 and IL‐6 protein levels. According to our findings, 3,5‐DBSA may treat glioblastoma. Significance This work analyzes 3,5‐DBSA's conformational search, characterization, molecular docking, and structural and anticancer properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Sciences, Necmettin Erbakan University, Konya, Türkiye.
- Department of Molecular Biology and Genetics, Necmettin Erbakan University, Konya, Türkiye.
- Department of Opticianry, Bayburt University, Bayburt, Türkiye.
- Department of Physics, Necmettin Erbakan University, Konya, Türkiye.
ORCID-Profile: Ebru Karakaş Sarıkaya, Suray Pehlivanoğlu
Zitieren
APA
Karakaş Sarıkaya, E., Pehlivanoğlu, S., Türkmen, M. Ö., Ekincioğlu, Y., Kostak, F., Çelik, S., & Dereli, Ö. (2025). Anticancer (cytotoxic, anticlonogenic, antimetastatic, immunomodulatory actions) properties of 3,5‐dibromosalicylaldehyde against glioblastoma cells and DFT analyses (FT‐IR, Raman, NMR, UV) as well as a molecular docking study. Biology of the Cell. https://doi.org/10.1111/boc.202400138
Vancouver
Karakaş Sarıkaya E, Pehlivanoğlu S, Türkmen MÖ, Ekincioğlu Y, Kostak F, Çelik S, et al. Anticancer (cytotoxic, anticlonogenic, antimetastatic, immunomodulatory actions) properties of 3,5‐dibromosalicylaldehyde against glioblastoma cells and DFT analyses (FT‐IR, Raman, NMR, UV) as well as a molecular docking study. Biology of the Cell. 2025. doi:10.1111/boc.202400138
BibTeX
@article{KarakaSarkaya2025,
author = {Karakaş Sarıkaya, Ebru and Pehlivanoğlu, Suray and Türkmen, Merve Özcan and Ekincioğlu, Yavuz and Kostak, Feyza and Çelik, Sultan and Dereli, Ömer},
title = {Anticancer (cytotoxic, anticlonogenic, antimetastatic, immunomodulatory actions) properties of 3,5‐dibromosalicylaldehyde against glioblastoma cells and DFT analyses (FT‐IR, Raman, NMR, UV) as well as a molecular docking study},
journal = {Biology of the Cell},
year = {2025},
doi = {10.1111/boc.202400138}
}
EUVIMED